WO2004089415A2 - COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST - Google Patents
COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST Download PDFInfo
- Publication number
- WO2004089415A2 WO2004089415A2 PCT/DK2004/000248 DK2004000248W WO2004089415A2 WO 2004089415 A2 WO2004089415 A2 WO 2004089415A2 DK 2004000248 W DK2004000248 W DK 2004000248W WO 2004089415 A2 WO2004089415 A2 WO 2004089415A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- methanone
- alkyl
- pyrazolo
- Prior art date
Links
- 0 CC=I1=C(*)C(C(N(*)*)O)=C2N1C(*)=C(*)C(*)=C2* Chemical compound CC=I1=C(*)C(C(N(*)*)O)=C2N1C(*)=C(*)C(*)=C2* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the instant invention involves a combination therapy comprising the administration of an 11 ?-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.
- Glucocorticoid receptor agonists are widely used as anti-inflammatory and disease- modifying treatment in a broad spectrum of diseases with an inflammatory component. Glucocorticoid receptor agonists are also used as a component of some forms of cancer chemotherapy. However, the use of glucocorticoid receptor agonists is often limited by severe side effects caused by glucocorticoid receptor agonism in organs and tissues that are not targets for treatment. These side effects include osteoporosis, decreased linear growth (children), aseptic bone necrosis, cushingoid fat distribution, mental changes, insulin resistance, hypertension, myopathy, cataract and glaucoma (Harrison's Principles of Internal Medicine, 14 th edition, Eds. Fauci et al., McGraw-Hill, New York, USA).
- glucocorticoid receptor agonists Like the endogenous active glucocorticoids (e.g. cortisol in humans, corticosterone in rodents), glucocorticoid receptor agonists bind to and stimulate ubiquitously expressed in- tracellular glucocorticoid receptors. Hence, the degree of receptor agonism depends on the intracellular concentration of ligand (reviewed e.g. in Yudt & Cidlowski, Mol Endocrinol; 16, 1719 (2002)).
- 11 ?-hydroxysteroid dehydrogenase type 1 (11 ?-HSD1) is an intracellular enzyme that physiologically catalyses the conversion of biologically inactive endogenous glucocorti- coid (e.g. cortisone in man, 11-dehydrocorticosterone in rodents) to active glucocorticoid (e.g. cortisol in man, corticosterone in rodents).
- 11 ?-HSD1 is expressed in several tissues and organs including the liver, adipose tissue, skeletal muscle, bone, pancreas, endothelium, ocular tissue and certain parts of the central nervous system.
- 11/?-HSD1 serves to increase the local levels of active endogenous glucocorticoid in many of the tissues and or- gans that are the origin of the side effects (but not the beneficial effects) of treatment with glucocorticoid receptor agonists(Tannin et al., J. Biol. Chem., 266, 16653 (1991); Bujalska et al., Endocrinology, 140, 3188 (1999); Whorwood et al., J. Clin. Endocrinol. Metab., 86, 2296 (2001); Cooper et al., Bone, 27, 375 (2000); Davani et al., J. Biol.
- the degree of stimulation of the glucocorticoid receptor will reflect the sum of contributions from the active endogenous glucocorticoid generated locally by 11 7-HSD1, the active endogenous glucocorticoid derived from plasma and the exogenous glucocoid receptor agonist. Consequently, inhibition of 11 ?-HSD1 decreases the total stimulation of the glucocorticoid receptor. Due to the expression pattern of 11 ?-HSD1 , levels of active glucocorticoid are decreased in the tissues and organs that are negatively affected by therapy with glucocorticoid receptor agonists while the desired therapeutic effects remain intact.
- a clinical case report demonstrates that a partial defect in/reduced activity of 11 ?-HSD1 abolishes the obesity and hypertension normally associated with Cushing's disease, i.e. increased pituitary ACTH secretion resulting in increased synthesis of cortisol in the adrenal glands (Tomlinson et al., J. Clin. Endocrinol. Metab., 87, 57 (2002).
- the instant invention addresses the clinical problems related to side effects of treatment with glucocorticoid receptor agonists by providing a combination therapy comprised of an 11 ?-HSD1 inhibitor and a glucocorticoid receptor agonist.
- a combination therapy comprised of an 11 ?-HSD1 inhibitor and a glucocorticoid receptor agonist.
- the 11 ?-HSD1 inhibitor together with the glucocorticoid receptor agonist allow for control of the disease while minimizing the side effects.
- dosage of the glucocorticoid receptor agonist can be optimized to meet the required therapeutic effect, providing improved means of achieving the desired clinical result.
- inhibitors and/or modulators of the human 11 ?-hydroxysteroid dehydrogenase type 1 enzyme can be found in WO 01/90090, WO 01/90091 , WO 01/90092, WO 01/90093, WO 01/90094, WO 02/72084 and WO 02/076435, as well as the following patent applications under common ownership of the present application: PA 2003 00569 filed 11 April 2003 DK, PA 2003 00565 filed 11 April 2003 DK, PA 2003 00571 filed 11 April 2003 DK, PA 200300570 filed 11 April 2003 DK, PA 2003 00566 filed 11 April 2003 DK, PA 200300972 filed 27 June 2003 DK, PA 2003 00998 filed 02 July 2003 DK, PA 2003 00988 filed 30 June 2003 DK, PA 200300989 filed 30 June 2003 DK, PA 2003 00990 filed 30 June 2003 DK, and PA 200301910 filed 22 December 2003 DK, the contents of which are hereby incorporated by reference in their entirety.
- An object of the present invention is to provide a novel combination therapy com- prised of a therapeutically effective amount of a glucocorticoid receptor agonist in combination with an 11jff-hydroxysteroid dehydrogenase type 1 (11 jff-HSDI) inhibitor for the reduction of undesirable side effects occurring during glucocorticoid receptor agonist therapy, and for treating some forms of cancer, diseases and disorders having inflammation as a component.
- 11jff-HSDI 11jff-hydroxysteroid dehydrogenase type 1
- halo includes fluorine, chlorine, bromine, and iodine.
- trihalomethyl includes trifluoromethyl, trichloromethyl, tr ibromomelhyl, and triiodomethyl.
- trihalomethoxy includes trifluorometoxy, trichlorometoxy, tribromometoxy, and triiodometoxy.
- alkyl includes C ⁇ -C 6 straight chain saturated and methylene aliphatic hydrocarbon groups, C 3 -C 6 branched saturated hydrocarbon groups having the specified num- ber of carbon atoms.
- this definition shall include but is not limited to methyl
- alkenyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and branched C 3 -C 6 unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- this definition shall include but is not limited to ethenyl, propenyl, butenyl, pentenyl, hexenyi, methylpropenyl, methylbutenyl and the like.
- alkynyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and C 4 -C 6 branched unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- this definition shall include but is not limited to ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylbutynyl, and the like.
- saturated or partially saturated cyclic, bicyclic or tricyclic ring system represents but are not limit to aziridinyl, pyrrolinyl, pyrrolidinyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, morpholinyl, piperidinyl, thiomorpholinyl, piperazinyl, phthalimide, 1,2,3,4- tetrahydro-quinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 1,2,3,4-tetrahydro-quinoxalinyl, and indolinyl.
- saturated or partially saturated cyclic ring system represents but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cydoheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl or tetrahydropyranyl.
- saturated or partially saturated aromatic ring system represents but are not limited to cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl or pyrimidinyl.
- cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohep- tyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[3.2.1]octyI, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl and the like
- cycloalkylalkyl e.g. cyclopropylmethyl, cyclobutylethyl, adamantylmethyl and the like
- cycloalkenyl e.g.
- cyclobutenyl represents a partially saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms.
- heteroalkyl (tetrahydrofuranyl, tetrahydropyranyl, tertahydrothiopyranyl, and the like) represents a saturated mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms and one or two additional heteroatoms or groups selected from nitrogen, oxygen, sulphur, SO or S0 2 .
- alkyloxy (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) represents an alkyl group as defined above having the indicated number of carbon atoms attached through an oxygen bridge.
- alkyloxyalkyl (e.g. methyloxymethyl and the like) represents an alkyloxy group as defined above attached through an “alkyl” group.
- aryloxyhetaryl e.g. 2-phenoxy-pyridyl and the like
- aryloxy e.g. phenoxy, naphthyloxy and the like
- hetaryloxy e.g. 2-pyridyloxy and the like
- arylalkyloxy e.g. phenethyloxy, naphthylmethyloxy and the like
- hetarylalkyloxy (e.g. 2-pyridylmethyloxy and the like) represents a hetarylalkyl group as defined below attached through an oxygen bridge.
- alkyloxycarbonyl e.g. methylformiat, ethylformiat and the like
- alkyloxycarbonyl represents an alkyloxy group as defined above attached through a carbonyl group.
- aryloxycarbonyl e.g. phenylformiat, 2-thiazolylformiat and the like
- aryloxycarbonyl represents an aryloxy group as defined above attached through a carbonyl group.
- arylalkyloxycarbonyl e.g. benzylformiat, phenyletylformiat and the like
- arylalkyl represents an "arylalkyloxy” group as defined above attached through a carbonyl group.
- arylalkyl e.g. benzyl, phenylethyl, 3-phenylpropyl, 1-naphtylmethyl, 2-(1- naphtyl)ethyl and the like
- hetarylalkyl e.g. (2-furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3- thienyl)methyl, (2-pyridyl)methyl, 1 -methyl-1 -(2-pyrimidyI)ethyl and the like
- hetarylalkyl represents a hetaryl group as defined below attached through an alkyl having the indicated number of carbon atoms or substituted alkyl group as defined above.
- alkylcarbonyl e.g. octylcarbonyl, pentylcarbonyl, 3-hexenylcarbonyl
- alkylcarbonyl represents an alkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
- arylcarbonyl e.g. benzoyl
- arylcarbonyl represents an aryl group as defined below attached through a carbonyl group.
- hetarylcarbonyl e.g. 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, oxazolylcarbonyl and the like
- hetarylcarbonyl represents a hetaryl group as defined below attached through a carbonyl group.
- carbonylalkyl e.g. acetyl and the like
- carbonylalkyl represents a carbonyl group attached through alkyl group as defined above having the indicated number of carbon atoms.
- alkylcarbonylalkyl e.g. propan-2-one, 4,4-dimethyl-pentan-2-one and the like
- alkylcarbonylalkyl represents an alkylcarbonyl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.
- arylcarbonylalkyl e.g. 1-phenyl-propan-1-one, 1-(3-chloro-phenyl)-2- methyl-butan-1-one and the like
- hetarylcarbonylalkyl e.g. 1-pyridin-2-yl-propan-1-one, 1-(1-H-imidazol-2- yl)-propan-1-one and the like
- hetarylcarbonylalkyl represents a hetarylcarbonyl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.
- arylalkylcarbonyl e.g. phenylpropylcarbonyl, phenylethylcarbonyl and the like
- hetarylalkylcarbonyl e.g. imidazolylpentylcarbonyl and the like
- alkyl group is in turn attached through a carbonyl.
- alkylcarboxy e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy
- alkylcarboxy represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
- arylcarboxy (e.g. benzoic acid and the like) represents an arylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
- alkylcarboxyalkyl e.g. heptylcarboxymethyl, propylcarboxy fe/t-butyl, 3- pentylcarboxyethyl
- arylalkylcarboxy e.g. benzylcarboxy, phenylpropylcarboxy and the like
- arylalkylcarboxyalkyl e.g. benzylcarboxymethyl, phenylpropylcarboxypro- pyl and the like
- arylalkylcarboxyalkyl represents an arylalkylcarboxy group as defined above wherein the carboxy group is in turn attached through an alkyl group as defined above having the indicated number of carbon atoms.
- hetarylcarboxy e.g. pyridine-2-carboxylic acid and the like
- hetarylalkylcarboxy e.g. (1-H-imidazol-2-yl)-acetic acid, 3-pyrimidin-2-yl- propionic acid and the like
- hetarylalkylcarboxy represents a hetarylalkyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
- alkylthio e.g. methylthio, ethylthio and the like
- arylthio e.g. benzenthiol, naphthylthiol and the like
- hetarylthio e.g. pyridine-2-thiol, thiazole-2-thiol and the like
- arylthioalkyl e.g. methylsulfanyl benzene, ethylsulfanyl naphthalene and the like
- alkyl group having the indicated number of carbon atoms.
- hetarylthioalkyl e.g. 2-methylsulfanyl-pyridine, 1-ethylsulfanyI-isoquinoline and the like
- hetarylthioalkyl represents a hetarylthio group as defined below attached through an alkyl group having the indicated number of carbon atoms.
- hetaryloxyaryl e.g. 1-phenoxy-isoquinolyl, 2-phenoxypyridyl and the like
- aryloxyaryl represents a hetaryloxy group as defined above attached through an “aryl” group as defined below.
- hetaryloxyhetaryl e.g. 1-(2-pyridyloxy-isoquinoline), 2-(imidazol-2-yloxy- pyridine) and the like
- hetaryloxyhetaryl represents a hetaryloxy group as defined above attached through a "hetaryl” group as defined below.
- aryloxyalkyl e.g. phenoxymethyl, naphthyloxyethyl and the like
- aryloxyaryl e.g. 1-phenoxy-naphthalene, phenyloxyphenyl and the like
- aryloxy group as defined above attached through an "aryl” group as defined below.
- arylalkyloxyalkyl (e.g. ethoxymethyl-benzene, 2-methoxymethyl- naphthalene and the like) represents an arylalkyloxy group as defined above attached through an “alkyl” group having the indicated number of carbon atoms.
- hetaryloxyalkyl e.g. 2-pyridyloxymethyl, 2-quinolyloxyethyl and the like
- hetaryloxyalkyl represents a hetaryloxy group as defined above attached through an “alkyl” group having the indicated number of carbon atoms.
- hetarylalkyloxyalkyl (e.g. 4-methoxymethyl-pyrimidine, 2-methoxymethyl- quinoline and the like) represents a hetarylalkyloxy group as defined above attached through an "alkyl” group having the indicated number of carbon atoms.
- alkylcarbonylamino (e.g. methylcarbonylamino, cyclopentylcarbonyl- aminomethyl, methylcarbonylaminophenyl) represents an "alkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group. The nitrogen atom may itself be substituted with an alkyl or aryl group.
- alkylcarbonylaminoalkyl e.g.N-propyl-acetamide, N-butyl-propionamide and the like
- alkylcarbonylamino represents an "alkylcarbonylamino" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- arylalkylcarbonylamino e.g. phenylacetamide, 3phenyl-propionamide and the like
- arylalkylcarbonylamino represents an “arylalkylcarbonyl” group as defined above attached through an amino group.
- arylalkylcarbonylaminoalkyl e.g. N-ethyl-phenylacetamide, N-butyl-3- phenyl-propionamide and the like
- arylcarbonylamino represents an "arylcarbonylamino” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- arylcarbonylamino e.g. benzamide, naphthalene-1 -carboxylic acid amide and the like
- arylcarbonylaminoalkyl e.g. N-propyl-benzamide, N-Butyl-naphthalene-1- carboxylic acid amide and the like
- arylcarbonylaminoalkyl represents an "arylcarbonylamino" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- aryl includes but is not limited to a carbocyclic aromatic ring system being either monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl and the like.
- Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic aromatic sys- terns enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1 ,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl and the like.
- heteroaryl includes but is not limited to pyrrolyl (2-pyrrolyl), pyrazolyl (3- pyrazolyl), imidazolyl (1 -imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3- triazol-1-yl, 1 ,2,3-triazol-2-yl 1,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yI), oxazolyl (2-oxazolyl, 4- oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiophenyl (2-thiophenyl, 3-thiophenyl, 4-thiophenyl, 5-thiophenyl), furanyl (2-fur
- NR 4 R 5 carbonylalkyl e.g. V, V-dimethyl- propionamide, /V-isopropyl-N-methyl-propionamide and the like
- alkylR 6 alkyl e.g. 2-ethoxymethyl, N-ethyl-N- methy amine, methyl-propyl-amide, ethanesulfonic acid methylamide and the like
- R 6 represents an alkyl group as defined above, substituted by R 6 , which is substituted by an alkyl group as defined above, wherein R 6 is as defined for Formula II herein.
- arylR 6 alkyl e.g. ethoxy-benzene, ethyl-methyl- phenyl-amine, ⁇ /-ethyl-benzamide, ⁇ /-isobutyl-benzenesulfonamide and the like
- R 6 represents an aryl group as defined above, substituted by R 6 , which is substituted by an alkyl group as defined above, wherein R 6 is as defined for Formula II herein.
- arylalkylR 6 alkyl e.g.
- benzyloxymethyl, ethyl- methyl-benzyl-amine, ⁇ /-ethyl-benzylamide and the like represents an arylalkyl group as defined above, substituted by R 6 , which is substituted by an alkyl group as defined above, wherein R 6 is as defined for Formula II herein.
- R 6 is as defined for Formula II herein.
- hetarylR 6 alkyl e.g.
- 2-ethoxy-1 /-/-imidazol, ethyI-quinolin-2-yl-amine, thiazole-2-carboxylic acid, methyl-propyl-amide, pyridine-3-sulfonic acid isobutyl-amide and the like) represents a hetaryl group as defined above, substituted by R 6 , which is substituted by an alkyl group as defined above, wherein R 6 is as defined for Formula II herein.
- arylcarbonylNR 15 e.g. ⁇ /-benzyl- ⁇ /-methyl- benzamide and the like
- alkylSO n (e.g. ethylsulfonyl, ethylsulfinyl and the like) represents an alkyl group as defined above, wherein the alkyl group is in turn at- tached through a sulphur bridge wherein the sulphur is substituted with n oxygen atoms, wherein n is as defined for Formula II herein.
- arylSO m (e.g. phenylsulfinyl, naphthyl-2-sulfonyl and the like) represents an aryl group as defined above, wherein the aryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms, wherein m is as defined for Formula II herein.
- hetarylSO m (e.g. thiazol-2-sulfinyl, pyridine-2- sulfonyl and the like) represents a hetaryl group as defined above, wherein the hetaryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms, wherein is as defined for Formula II herein.
- arylSO m NR 8 e.g.
- NR 4 R 5 carbonylalkyl (e.g.
- ⁇ /, ⁇ -dimethyl- propionamide, ⁇ /-isopropyl- ⁇ /-methyl-propionamide and the like represents NR R 5 substituted by a carbonylalkyl group as defined above, wherein R 4 and R 5 are as defined for Formula V herein.
- arylR 8 alkyl e.g. ethoxy-benzene, N-ethyl-N- methyl-phenyl-amine, ⁇ /-ethyl-benzamide, /V-isobutyl-benzenesutfonamide and the like
- R 8 represents an aryl group as defined above, substituted by R 8 , which is substituted by an alkyl group as defined above, wherein R 8 is as defined for Formula V herein.
- hetaryl R 8 alkyl e.g. 2-ethoxy-1H-imidazol, ethyl-quinolin-2-yl-amine, thiazole-2-carboxylic acid, methyl-propyl-amide, pyridine-3-sulfonic acid isobutyl-amide and the like
- R 8 represents a hetaryl group as defined above, substituted by R 8 , which is substituted by an alkyl group as defined above, wherein R 8 is as defined for Formula V herein.
- arylcarbonylNR 15 (e.g. ⁇ /-benzyl- ⁇ /-methyl- benzamide and the like) represents an arylcarbonyl group as defined above, substituted by NR 15 , wherein R 15 is as defined for Formula V herein.
- treatment is defined as the management and care of a patient for the purpose of combating or alleviating the disease, condition or disorder, and the term includes the administration of the active compound to prevent the onset of the symptoms or complica- tions, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- pharmaceutically acceptable is defined as being suitable for administration to humans without adverse events.
- prodrug is defined as a chemically modified form of the active drug, said prodrug being administered to the patient and subsequently being converted to the active drug. Techniques for development of prodrugs are well known in the art.
- the term "combination therapy” is defined as the administration of a single pharmaceutical dosage formulation which comprises the 11 ?-HSD1 inhibitor and the glucocorticoid receptor agonist, as well as administration of each active agent in its own separate pharma- ceutical dosage formulation. Where separate dosage formulations are used, the 11 7-HSD1 inhibitor and the glucocorticoid receptor agonist can be administered to the patient at essentially the same time, i.e. concurrently, or at separate staggered times, i.e. sequentially. When given by different dosage formulations, the route of administration may be the same or different for each agent. Any route of administration known or contemplated for the individual agents is acceptable for the practice of the present invention.
- the term "therapeutically effective amount” is defined as the amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system or a mammal that is sought by the treating individual, i.e. medical doctor or other clinician.
- modulation are intended to include stimulation (e.g., increasing or upregulating a particular response or activity) and inhibition (e.g., decreasing or downregulating a particular response or activity).
- agonist is intended to indicate a substance that activates the receptor(s).
- glucocorticoid receptor agonist is intended to indicate a substance that activates glucocorticoid receptor(s) without dependence on prior modification of the substance by 11 ⁇ HSD1.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I)
- R 6 and R 7 independently are C ⁇ -C ⁇ alkyl, C 3 -C 10 cycloalkyl, hetC 3 -C ⁇ 0 cycloalkyl, arylCrC 6 alkyl or hetarylC C 6 alkyl, wherein the alkyl, cycloalkyl, hetcycloalkyl, arylalkyl, and hetarylalkyl groups independently are optionally substituted with one or more of R 10 ; or
- R 6 and R 7 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulphur, the ring system optionally being substituted with at least one of CrC 6 alkyl, aryl, hetaryl, arylC C 6 alkyl, halo, hydroxy, oxo, C C 6 alkyloxy, arylCrCealkyloxy, hetarylCrCealkyloxy, d- C 6 alkyloxyCrC 6 alkyl, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, CrC 6 alkylcarboxy, arylcarboxy, hetarylcarboxy
- R 8 and R 9 independently are hydrogen, halo, hydroxy, oxo, cyano, nitro, C 3 -C 10 cycloalkyl, C 3 - C 10 hetocycloalkyl, d-Cealkyl, d-Cealkyloxy, trihalomethyl, trihalomethoxy, aryld-Cealkyloxy, hetarylC C 6 alkyloxy, d-Cealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, d-C 6 alkylcarboxy, arylcarboxy, hetarylcarboxy, aryld-Ce- alkylcarboxy, hetarylCrC 6 alkylcarboxy, CrC 6 alkylcarbonylamino or arylCrC 6 alkylcarbonyl-
- R 10 is hydrogen, halo, cyano, nitro, hydroxy, oxo, C 3 -C 10 cycloalkyl, C 3 -C 10 hetcycloalkyl, Ci- Cealkyl, CrC 6 aIkyloxy, trihalomethyl, trihalometh dialkylamino oxy, aryld-Cealkyloxy, hetarylCrCealkyloxy, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, CrC 6 alkylcarboxy, arylcarboxy or arylCrC 6 alkylcarboxy;
- R 11 is d-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryld-Cealkyl, hetarylCrCealkyl, d-C 6 alkyl- carbonylCrC 6 alkyl, CrC 6 alkyloxy, aryloxy, CrC 6 alkyloxy, arylcarbonyl, arylCrCealkylcarbonyl, hetarylcarbonylCrC 6 alkyl, wherein the alkyl, alkenyl, alkynyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 9 ;
- R 2 is CrC 6 alkylcarbonyIaminoCrC 6 alkyl, arylcarbonylaminoCrC 6 alkyl or arylCrC 6 alkyl- carbonylaminoCrC 6 alkyl;
- R 13 and R 14 independently are hydrogen, oxo, C 3 -C 10 cycloalkyl, CrC 6 alkyl, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrC 6 alkylcarbonyl, hetarylCrCealkylcarbonyl;
- R 15 is hydrogen, C 3 -C 10 cycloalkyl, CrC 6 alkyl, aryl, hetaryl, arylCrC 6 alkyl, hetarylCrCealkyl, CrC 6 alkyloxyalkyl or arylGrC 6 alkyloxyalkyl; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
- R 3 and R 5 independently are hydrogen, NR 13 R 14 trihalomethyl, trihalomethoxy, d-Cealkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, CrC 6 alkyloxy, CrC 6 alkylthio, aryl, arylCrC 6 alkyl, hetaryl or hetarylCrCealkyl, wherein alkyl, alkynyl, alkenyl, aryl, hetaryl, arylalkyl or hetarylalkyl groups independently are optionally substituted with one or more of R 8 ;
- R 6 and R 7 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulphur, the ring system optionally being substituted with at least one of CrC ⁇ alkyl, aryl, hetaryl, aryld- C 6 alkyl, halo, hydroxy, oxo, CrC 6 alkyloxy, arylCrCealkyloxy, hetarylCrCealkyloxy, d-C 6 - alkyloxyd-C 6 alkyl, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, CrC 6 alkylcarboxy, arylcarboxy, hetaryl
- R 8 and R 9 independently are hydrogen, halo, hydroxy, oxo, cyano, nitro, C 3 -d -cycloalkyl, C 3 - dohetocycloalkyl, d-C 6 alkyl, CrC 6 alkyloxy, trihalomethyl, trihalomethoxy, arylCrCealkyloxy, hetarylCrCealkyloxy, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrC 6 aIkylcarbonyl, CrCealkylcarboxy, arylcarboxy, hetarylcarboxy, aryld- C 6 alkylcarboxy, hetarylCrC 6 alkylcarboxy, d-Cealkylcarbonylamino or arylCrC 6 alkyl- carbonylamino;
- R 10 is hydrogen, halo, cyano, nitro, hydroxy, oxo, C 3 -C 10 cycloalkyl, C 3 -C 10 hetcycloalkyl, Ci- Cealkyl, CrC 6 alkyloxy, trihalomethyl, trihalometh dialkylamino oxy, arylCrCealkyloxy, hetarylCrCealkyloxy, CrC 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylC C 6 alkylcarbonyl, hetarylCrC 6 alkylcarbonyl, CrC 6 alkylcarboxy, arylcarboxy or aryld- C 6 alkylcarboxy;
- R 11 is Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, arylCrC 6 alkyl, hetaryld-Cealkyl, C C 6 alkyl- carbonylCrC 6 alkyl, d-C 6 alkyl, arylcarbonyl, arylCrCealkylcarbonyl, hetarylcarbonylCrC 6 - alkyl, wherein the alkyl, alkenyl, alkynyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 9 ;
- R 12 is CrC 6 alkylcarbonylaminoCrC 6 alkyl, arylcarbonylaminoCrC 6 alkyl or arylCrC 6 alkyl- carbonylaminoCrC 6 alkyl;
- R 13 and R 14 independently are hydrogen, oxo, C 3 -C 10 cycloalkyl, CrC 6 alkyl, CrC 6 alkyloxy, trihalomethyl, trihalomethoxy, arylCrCealkyloxy, hetaryld-Cealkyloxy, d-C 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, CrCealkylcarboxy, arylcarboxy, hetarylcarboxy, arylCrCealkylcarboxy;
- R 15 is hydrogen, C 3 -C ⁇ 0 cycloalkyl, CrCealkyl, aryl, hetaryl, arylCrCealkyl, hetarylCrC 6 alkyl, CrC 6 alkyloxyalkyl or arylCrC 6 alkyloxyalkyl; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
- said substituted pyrazoIo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 3 and R 5 independently are hydrogen, trihalomethyl, CrC 6 alkyl, CrC 6 alkyloxy, aryl, arylCrC 6 alkyl, hetaryl or hetaryld-Cealkyl, wherein alkyl, aryl, hetaryl, arylalkyl or hetarylalkyl groups independently are optionally substituted with one or more of R 8 .
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 6 and R 7 independently are CrC 6 alkyl, C 3 -C ⁇ 0 cycloalkyl, hetC 3 - Ciocycloalkyl, arylCrC 6 alkyl or hetarylCrCealkyl, wherein the alkyl, cycloalkyl, hetcycloalkyl, arylalkyl, and hetarylalkyl groups independently are optionally substituted with one or more of R 10 .
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I)
- R 6 and R 7 together with the nitrogen to which they are attached are form- ing a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen, the ring system optionally being substituted with at least one of C ⁇ -C ⁇ alkyl, aryl, hetaryl, arylCrC 6 alkyl, halo, hydroxy, oxo, CrC 6 alkyloxy, arylCrCealkyloxy, hetarylCrCealkyloxy, d- C 6 alkyloxyCrC 6 alkyl, d-Cealkylcarbonyl, arylcarbonyl, hetarylcarbonyl,
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 6 and R 7 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional nitrogen atoms, the ring system optionally being substituted with at least one of CrCealkyl, aryl, hetaryl, aryld-Cealkyl, halo, hydroxy, oxo, CrC 6 alkyloxy, arylCrCealkyloxy, hetarylCrCealkyloxy, CrCealkyloxyCrCealkyl.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 8 and R 9 independently are hydrogen, halo, hydroxy, oxo, cyanoC 3 -C 10 cycloalkyl, G 3 -dohetocycloalkyl, d-Cealkyl, C C 6 alkyloxy, trihalomethyl, aryld- C 6 alkyloxy, hetarylCrCealkyloxy.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 10 is hydrogen, halo, cyano, nitro, hydroxy, oxo, C 3 -d 0 cyclo- alkyl, C 3 -C ⁇ 0 hetcycloalkyl, d-Cealkyl, CrC e alkyloxy, arylCrCealkyloxy, hetarylCrCealkyloxy, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, d-Cealkylcarboxy, arylcarboxy or arylCrCealkylcarboxy.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 11 is d-Cealkyl, arylCrC 6 aIkyl, hetarylCrCealkyl, CrC 6 alkyloxy, aryloxy, CrC 6 alkyIoxy, wherein the alkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 9 .
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 12 is CrC 6 alkylcarbonylaminoCrC 6 alkyl, arylcarbonylaminod- C 6 alkyl or arylCrCealkylcarbonylaminoCrC ⁇ alkyl.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 13 and R 14 independently are hydrogen, C 3 -C ⁇ 0 cycloalkyl, Ci- Cealkyl, CrC 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is of the general formula (I) wherein R 15 is hydrogen, C 3 -C ⁇ 0 cycloalkyl, d-C 6 alkyl, aryl, hetaryl, aryld- Cealkyl, hetarylCrCealkyl, d-C 6 alkyloxyalkyl or aryld-C 6 alkyloxyaIkyl.
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is selected from the group consisting of: (3-Bromo-5-thiophen-2-yl-7-trifluoromethyl-pyrazolo[1 ,5-a]pyrimidin-2-yl)-(2,6-dimethyl- piperidin-1 -yl-)methanone;
- said substituted pyrazolo[1 ,5- ajpyrimidines, or a prodrug thereof, as a component of the combination therapy is selected from the group of
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II)
- R 1 is C 3 -C ⁇ ocycloalkyl, C 3 -C 10 hetcycloalkyl, CrC 8 alkyl, aryl, hetaryl, aryld-C 6 alkyl or hetarylCrCealkyl, wherein the cycloalkyl, hetcycloalkyl, alkyl, arylalkyl and hetarylalkyl groups independently are optionally substituted with one or more of R 4 .
- R 2 is hydrogen, d-C 8 alkyI, aryl, hetaryl, arylCrCealkyl, C 3 -C ⁇ ocycloalkylCrC 6 alkyl, d- C 6 alkyl-carboxyCrC 6 alkyl wherein the alkyl, aryl and cycloalkyl groups independently are optionally substituted with one or more of R 5 ; or
- R 1 and R 2 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulphur, the ring system optionally being substituted with at least one of C C 8 alkyl, aryl, hetaryl, aryld- C 6 alkyl, hetarylCrCealkyl, hydroxy, oxo, cyano, d-C 6 alkyloxy, aryld-Cealkyloxy, hetaryld- Cealkyloxy, CrCealkyloxyCrCealkyl, d-Cealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, d-Cealkylcarbox
- R 3 is CrC 8 alkyl, d-C 6 alkenyl, C ⁇ -C 6 alkynyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C 10 hetcycloalkyl, aryl, hetaryl, arylCrC 6 alkyl, d-Cealkyloxyd-Cealkyl, hetarylCrCealkyl, aryl-R 6 -CrC 6 alkyI, hetaryl- R 6 -CrC 6 alkyl or arylCrCealkyl-R ⁇ CrCealkyl wherein the alkyl, cycloalkyl, hetcycloalkyl, alkenyl, alkynyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 7 ;
- R 4 and R 5 independently are hydrogen, hydroxy, oxo, cyano, halo, methylendioxo, NR 8 R 9 , CrC 8 alkyl, CrC 6 alkyloxy, trihalomethyl, trihalomethyloxy, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 hetcyclo- alkyl, C 3 -C ⁇ 0 cycloalkenyl, aryl, hetaryl, hetarylSO n , arylCrCealkyloxy, hetaryld-Cealkyloxy, CrC 6 alkyl-R 6 -C ⁇ -C 6 alkyl, arylCrC 6 alkyl-R 6 -CrC 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylCrCealkylcarbonyl, hetarylcarbonyl, hetarylCrC
- R° is oxygen, sulphur, SO n or NR 16.
- R 7 is hydrogen, halo, hydroxy, cyano, nitro, COOR 17 , d-C 8 alkyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 het- cycloalkyl, methylendioxo, trihalomethyl, trihalomethyloxy, aryl, arylCrC 6 alkyl, CrCealkyloxy, CrCealkyloxyCrCealkyl, aryloxy, arylCrCealkyloxy, aryloxyd-Cealkyl, arylCrC 6 alkyloxyCr C 6 alkyl, hetaryl, hetarylCrCealkyl, hetaryloxy, hetarylCrCealkyloxy, hetaryloxyCrCealkyl, he-aryld-Ce
- R 8 and R 9 independently are hydrogen, CrC 8 alkyl, aryl, hetaryl, aryld-C 6 alkyl or hetaryld- Cealkyl wherein the alkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 11 ; or
- R 8 and R 9 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system optionally being substituted with at least one halo, cyano, CrC 8 alkyl, aryl, hetaryl, arylCrC 6 alkyl, hetaryld-Cealkyl, hydroxy, oxo, CrC 6 alkyloxy, aryld-Cealkyloxy, hetaryld- Cealkyloxy, CrC 6 alkyloxyC 1 -C 6 alkyl ) d-C 6 alkyl-carbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, d-C 6 alkyl
- R 10 and R 11 independently are hydrogen, hydroxy, oxo, halo, cyano, nitro, CrC 8 alkyl, d- C 6 alkyloxy, NR 12 R 13 , methylendioxo, trihalomethyl or trihalomethyloxy;
- R 12 and R 13 independently are hydrogen, d-C 8 alkyl or arylCrC 6 alkyl
- R 14 is hydrogen, halo, hydroxy, oxo, nitro, cyano, d-C 8 alkyl, d-C 6 alkyloxy or aryloxy;
- R 15 is hydrogen, halo, hydroxy, oxo, nitro, cyano, CONR 8 R 9 or COOR 17 ;
- R 16 is hydrogen, CrC 8 alkyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, aryl, arylCrC 6 alkyl, hetaryl, hetarylCrCealkyl, alkylcarbonyl, arylcarbonyl, arylCrC 6 alkylcarbonyl, aryloxyd- Cealkyl, hetaryloxyCrC 6 alkyl, arylthioCrCealkyl or hetarylthioCrC 6 alkyl; wherein the alkyl, cycloalkyl, hetcycloalkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 10 ;
- R is hydrogen, CrC ⁇ alkyl, aryl or arylCrCealkyl
- R 18 is CrCealkyl, C 2 -C 6 alkenyl, aryl, arylCrC 6 alkyI, hetaryl, hetarylCrCealkyl, C 3 - Ciocycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, CrC 6 alkyloxy, aryloxy, arylCrCealkyloxy, aryld- CealkyIoxyC ⁇ -C 6 alkyl, hetaryloxy, hetarylCrC 6 alkyloxy, hetarylCrCealkyloxyCrCealkyl or R 8 R 9 NCrC 6 alkyl wherein the alkyl, alkenyl, cycloalkyl, hetcycloalkyl, aryl and hetaryl groups are optionally substituted with R 15 ;
- R 19 is CrC 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, aryl, arylCrC 6 alkyl, hetaryl, hetaryld-Cealkyl;
- n 1 or 2;
- n 0, 1 or 2;
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein: R 1 is C 3 -Ci 0 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, d-C 8 alkyl, aryl, hetaryl, aryld-C 6 alkyl or hetaryld-Cealkyl, wherein the cycloalkyl, hetcycloalkyl, alkyl, arylalkyl and hetarylalkyl groups independently are optionally substituted with one or more of R 4 ;
- R 2 is hydrogen, C C 8 alkyl, aryl, hetaryl, arylCrC 6 alkyl, C 3 -C ⁇ 0 cycloalkylCrC 6 alkyI, C C 6 - alkylcarboxyCrC 6 alkyl wherein the alkyl, aryl and cycloalkyl groups independently are optionally substituted with one or more of R 5 ; or
- R 1 and R 2 are together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulphur, the ring system optionally being substituted with at least one of CrC 8 alkyl, aryl, hetaryl, aryld- C 6 alkyl, hetarylCrCealkyl, hydroxy, oxo, cyano, CrC 6 alkyloxy, aryld-C 6 alkyloxy, hetaryld- Cealkyloxy, CrCealkyloxyCrCealkyl, CrCealkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrCealkylcarbonyl, CrCealkylcarboxy, aryl
- R 3 is CrC 8 alkyl, CrC 6 alkenyl, CrC 6 alkynyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, aryl, hetaryl, arylCrC 6 alkyl, CrCealkyloxyCrCealkyl, hetarylCrCealkyl, aryl-R 6 -CrC 6 alkyl, hetaryl- R 6 -CrC 6 alkyl or arylC ⁇ -C6alkyl-R 6 -CrC 6 alkyl wherein the alkyl, cycloalkyl, hetcycloalkyl, alkenyl, alkynyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 7 ;
- R 4 and R 5 independently are hydrogen, hydroxy, oxo, cyano, halo, methylendioxo, NR 8 R 9 , CrC 8 alkyl, CrC 6 alkyloxy, trihalomethyl, trihalomethyloxy, C 3 -C ⁇ 0 cycloalkyl, C 3 -
- Ciohetcycloalkyl C 3 -C ⁇ 0 cycloalkenyl, aryl, hetaryl, hetarylSO n , arylCrC 6 alkyloxy, he-aryld- C 6 alkyloxy, CrC 6 alkyl-R 6 -CrCealkyl, arylC ⁇ -C 6 alkyl-R 6 -CrC 6 alkyl, CrCealkylcarbonyl, arylcarbonyl, arylCrCealkylcarbonyl, hetarylcarbonyl, hetarylCrC 6 alkyl-carbonyl, C ⁇ -C 6 alkylSO n , CrC 6 alkyl-carboxy, arylcarboxy, hetarylcarboxy, arylCrC 6 alkylcarboxy or hetarylCrC 6 alkyl- carboxy wherein the alkyl, cycloalkyl,
- R 8 is oxygen, sulphur, SO n , NR 16 ;
- R 7 is hydrogen, halo, hydroxyl, cyano, nitro, COOR 17 , CrC 8 alkyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 het- cycloalkyl, methylendioxo, trihalomethyl, trihalomethyl, trihalomethyloxy, aryl, arylCrCealkyl, CrC 6 alkyloxy, CrCealkyloxyCrCealkyl, aryloxy, aryloxyCrC 6 alkyl, arylCrCealkyloxyCrCealkyl, hetaryl, hetarylCrCealkyl, hetaryloxy, hetarylCrCealkyloxy, hetaryloxyCrCealkyl, hetarylCrCealkyloxyCrCealkyl, NR 8 R 9 , S0 2 NR 8 R 9
- C 6 alkyIR 6 CrC 6 alkyl wherein the aryl and hetaryl groups independently are optionally substituted with one or more R 10 ;
- R 8 and R 9 independently are hydrogen, CrC 8 alkyl, aryl, hetaryl, arylCrCealkyl or hetaryld- C 6 alkyl wherein the alkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 11 ; or
- R 8 and R 9 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system optionally being substituted with at least one d-C 8 alkyl, aryl, hetaryl, arylCrCealkyl, hetarylCrC 6 alkyl, hydroxy, oxo, CrC 6 alkyloxy, aryld-Cealkyloxy, hetarylCrCealkyloxy, d- CealkyloxyCrCealkyl, CrC 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrCealkylcarbonyl, hetarylCrC 6 alkylcarbonyl, CrC 6 alkylcarboxy, arylcarboxy,
- R 10 and R 11 independently are hydrogen, hydroxy, oxo, halo, cyano, nitro, d-Cealkyl, d-C 6 - alkyloxy, NR 12 R 13 , methylendioxo, trihalomethyl or trihalomethyloxy;
- R 12 and R 13 independently are hydrogen, C ⁇ -C 8 alkyl or arylCrC 6 alkyl
- R 14 is hydrogen, halo, hydroxy, oxo, nitro, cyano, C C 8 alkyl, CrC 6 alkyloxy or aryloxy;
- R 15 is hydrogen, halo, hydroxy, oxo, nitro, cyano or COOR 17 ;
- R 16 is hydrogen, CrC 8 alkyl, C 3 -C ⁇ 0 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, aryl, arylCrC 6 alkyl, hetaryl, hetarylCrCealkyl, alkylcarbonyl, arylcarbonyl, arylCrCealkylcarbonyl, aryloxyd- C 6 alkyl, hetaryloxyCrCealkyl, arylthioCrC 6 alkyl or hetarylthioCrC 6 alkyl; wherein the alkyl, cycloalkyl, hetcycloalkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 10 ;
- R 17 is hydrogen, CrC 8 alkyI, aryl or aryld-C 6 alkyl
- n 1 or 2;
- n 0, 1 or 2; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 1 is C 3 -C ⁇ 0 cycloalkyl or C 3 -C ⁇ ohetcycloalkyl wherein the cycloalkyl and hetcycloalkyl groups independently are optionally substituted with one or more of R 4 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 1 is C 3 -C ⁇ 0 cycloalkyl optionally substituted with one or more of R 4 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 2 is hydrogen or d-C 8 alkyl, wherein the the alkyl group is optionally substituted with one or more of R 5 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 2 is d-G 8 alkyl optionally substituted with one or more of R 5 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is o the general formula (II) wherein R 3 is C 3 -C 10 cycloalkyl, C 3 -C ⁇ 0 hetcycloalkyl, aryl, hetaryl, arylC C 6 alkyl, hetaryld- Cealkyl, aryl-R 6 -CrC 6 alkyl, hetaryI-R 6 -CrC 6 alkyl or arylCrC 6 alkyl-R 6 -CrC 6 alkyl wherein the alkyl, cycloalkyl, hetcycloalkyl, aryl and hetaryl groups independently are optionally substituted with one or more of R 7 .
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 3 is aryl or hetaryl, wherein the aryl and hetaryl groups are optionally substituted with one or more of R 7 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 3 is is phenyl optionally substituted with one or more of R 7 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 3 is phenyl optionally substituted independently in position 2(ortho) or 4(para) with one or more of R 7 as defined above.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 4 and R 5 independently are hydrogen, hydroxy, oxo, halo, CrC 8 alkyl, wherein the alkyl group is optionally substituted with one ore more of R 15 .
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 6 is oxygen.
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 7 is hydrogen, halo, hydroxy, cyano, d-C 8 alkyI, C 3 -C 10 cycloalkyl, C 3 -C 10 het- cycloalkyl, trihalomethyl, aryl, arylCrC 6 alkyl, CrC 6 alkyloxy, CrCealkyloxyCrCealkyl, aryloxy, arylCrCealkyloxy, aryloxyCrC 6 alkyl, arylCrCealkyloxyCrCealkyl, hetaryl, hetaryld-Cealkyl, hetaryloxy, hetarylCrCealkyloxy, hetaryloxyCrCealkyl, hetaryld-Cealkyl-oxy, hetaryl
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 8 and R 9 together with the nitrogen to which they are attached, are forming a saturated or partially saturated cyclic, bicyclic or tricyclic ring system containing from 4 to 10 car- bon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system optionally being substituted with at least one halo, cyano, d-C 8 alkyl, aryl, hetaryl, aryld-Cealkyl, hetarylCrCealkyl, hydroxy, oxo, CrC 6 alkyloxy, arylCrC 6 alkyloxy, hetarylCrCealkyloxy, CrCealkyloxyd-Cealkyl, CrC 6 alkyl-carbonyl, arylcarbonyl, hetarylcarbonyl,
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 15 is CONR 8 R 9 .
- said substituted amides, or a pro- drug thereof, as a component of the combination therapy is of the general formula (II) wherein R 18 is d-C 6 alkyl optionally substituted with R 15 .
- said substituted amide, or a prodrug thereof, as a component of the combination therapy is selected from the group consisting of: 3-(10, 11 -Dihydro-dibenzo[b,f]azepin-5-yl)-1 -[4-(1 H-imidazol-4-yl)-piperidin-1 -yl]-propan-1 - one; 4-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-1-[4-(3H-imidazol-4-yl)-piperidin-1-yl]-butan-1-one;
- Azepan-1-yl-(4-chloro-phenyl)-methanone 3-Heptylcarbamoyl-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid; Adamantan-1 -yl-azepan-1 -yl-methanone;
- Naphthalene-2-carboxyIic acid (2-oxo-azepan-3-yl)-thiophen-3-ylmethyl-amide; 3,4,5-Trimethoxy-N-(4-methyl-benzyl)-N-[6-(pyridin-2-ylamino)-hexyl]-benzamide; 3-Cyclopentyl-N-(4-methyl-benzyl)-N-[6-(pyridin-2-ylamino)-hexyl]-propionamide;
- Acetic acid 4-(3,5-dimethyl-piperidine-1-carbonyl)-phenyl ester; (4-Chloro-3-nitro-phenyl)-(2,6-dimethyl-piperidin-1-yl)-methanone;
- Furan-2-carboxylic acid [4-(4-methyl-piperidine-1 -sulfonyl)-phenyl]-amide;
- Cyclohexanecarboxylic acid (2-phenylsulfanyl-phenyl)-amide; (4-Hydroxy-4-phenyl-octahydro-quinolin-1-yl)-phenyl-methanone;
- N-Benzyl-4-bromo-N-ethyl-benzamide (3-Methyl-piperidin-1 -yl)-[4-(naphthalen-1 -yloxymethyl)-phenyl]-methanone;
- N-Benzyl-N-cyclohex-1-enyl-isonicotinamide 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2-(2-methyl-benzylsulfanyl)-ethanone; 2-(2-Bromo-4-methyl-phenoxy)-N-(2-cyclohex-1-enyl-ethyl)-acetamide;
- Benzo[b]thiophene-3-carboxylic acid (3,3,5-trimethyl-cyclohexyl)-amide; 2-(2,6-Dimethyl-phenoxy)-N-(2-isopropyl-phenyl)-acetamide;
- 6-Oxo-6-phenyl-hexanoic acid (4-hydroxy-benzyl)-(4-trifluoromethyl-benzyl)-amide; 2-(3,4-Difluoro-phenyl)-N-(4-hydroxy-benzyl)-N-thiophen-2-ylmethyl-acetamide;
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006504351A JP2006522744A (ja) | 2003-04-11 | 2004-04-06 | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
EP04725890A EP1615667A2 (en) | 2003-04-11 | 2004-04-06 | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
US11/246,814 US20060094699A1 (en) | 2003-04-11 | 2005-10-07 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US12/491,659 US20090264412A1 (en) | 2003-04-11 | 2009-06-25 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy |
Applications Claiming Priority (58)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300569 | 2003-04-11 | ||
DKPA200300569 | 2003-04-11 | ||
DKPA200300568 | 2003-04-11 | ||
DKPA200300568 | 2003-04-11 | ||
DKPA200300565 | 2003-04-11 | ||
DKPA200300570 | 2003-04-11 | ||
DKPA200300571 | 2003-04-11 | ||
DKPA200300565 | 2003-04-11 | ||
DKPA200300570 | 2003-04-11 | ||
DKPA200300566 | 2003-04-11 | ||
DKPA200300566 | 2003-04-11 | ||
DKPA200300571 | 2003-04-11 | ||
US46780003P | 2003-05-02 | 2003-05-02 | |
US46728403P | 2003-05-02 | 2003-05-02 | |
US46736203P | 2003-05-02 | 2003-05-02 | |
US46744303P | 2003-05-02 | 2003-05-02 | |
US46745303P | 2003-05-02 | 2003-05-02 | |
US46736303P | 2003-05-02 | 2003-05-02 | |
US60/467,284 | 2003-05-02 | ||
US60/467,453 | 2003-05-02 | ||
US60/467,363 | 2003-05-02 | ||
US60/467,362 | 2003-05-02 | ||
US60/467,443 | 2003-05-02 | ||
US60/467,800 | 2003-05-02 | ||
DKPA20030778 | 2003-05-22 | ||
DKPA200300778 | 2003-05-22 | ||
DKPA200300776 | 2003-05-22 | ||
DKPA200300776 | 2003-05-22 | ||
US47519503P | 2003-06-02 | 2003-06-02 | |
US47515703P | 2003-06-02 | 2003-06-02 | |
US60/475,157 | 2003-06-02 | ||
US60/475,195 | 2003-06-02 | ||
DKPA200300972 | 2003-06-27 | ||
DKPA200300972 | 2003-06-27 | ||
DKPA200300988 | 2003-06-30 | ||
DKPA200300990 | 2003-06-30 | ||
DKPA200300988 | 2003-06-30 | ||
DKPA200300989 | 2003-06-30 | ||
DKPA200300990 | 2003-06-30 | ||
DKPA200300989 | 2003-06-30 | ||
DKPA200300998 | 2003-07-02 | ||
DKPA200300998 | 2003-07-02 | ||
US48609403P | 2003-07-10 | 2003-07-10 | |
US48609803P | 2003-07-10 | 2003-07-10 | |
US48609503P | 2003-07-10 | 2003-07-10 | |
US48607803P | 2003-07-10 | 2003-07-10 | |
US48609703P | 2003-07-10 | 2003-07-10 | |
US60/486,097 | 2003-07-10 | ||
US60/486,095 | 2003-07-10 | ||
US60/486,078 | 2003-07-10 | ||
US60/486,094 | 2003-07-10 | ||
US60/486,098 | 2003-07-10 | ||
DKPA200301910 | 2003-12-22 | ||
DKPA200301910 | 2003-12-22 | ||
DKPA200400009 | 2004-01-06 | ||
DKPA200400009 | 2004-01-06 | ||
US53709904P | 2004-01-16 | 2004-01-16 | |
US60/537,099 | 2004-01-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/246,814 Continuation US20060094699A1 (en) | 2003-04-11 | 2005-10-07 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004089415A2 true WO2004089415A2 (en) | 2004-10-21 |
WO2004089415A3 WO2004089415A3 (en) | 2005-03-10 |
Family
ID=33163367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000248 WO2004089415A2 (en) | 2003-04-11 | 2004-04-06 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1615667A2 (ja) |
JP (1) | JP2006522744A (ja) |
WO (1) | WO2004089415A2 (ja) |
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005090320A2 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | Triazole derivatives and method of using the same to treat hiv infections |
WO2006023844A2 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
WO2006046915A1 (en) * | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Use of unsaturated quionoline or naphtalene derivatives as medicaments |
JP2006522748A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
WO2006132436A1 (ja) * | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | 複素環化合物 |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
WO2006024627A3 (en) * | 2004-08-30 | 2007-09-13 | Janssen Pharmaceutica Nv | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
WO2007117398A2 (en) * | 2006-03-30 | 2007-10-18 | Summerton James E | Non-peptidic molecules for detecting and treating tumors |
WO2007139951A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
WO2008019302A1 (en) * | 2006-08-04 | 2008-02-14 | Decode Genetics Ehf | Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation |
WO2008029168A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
JP2008520702A (ja) * | 2004-11-18 | 2008-06-19 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
WO2008101914A2 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008101885A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008101886A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008121126A1 (en) * | 2007-03-30 | 2008-10-09 | Summerton James E | Non-peptidic molecules for detecting and treating tumors |
WO2008134035A1 (en) * | 2007-04-27 | 2008-11-06 | Panacos Pharmaceuticals, Inc. | Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives |
JP2008546714A (ja) * | 2005-06-17 | 2008-12-25 | アポジー・バイオテクノロジー・コーポレイション | スフィンゴシンキナーゼ阻害剤 |
WO2008121386A3 (en) * | 2007-03-30 | 2008-12-31 | Amgen Inc | Calcimimetic compounds for use in the treatment of bowel disorders |
WO2009015067A2 (en) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
FR2929851A1 (fr) * | 2008-04-09 | 2009-10-16 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7662813B2 (en) | 2005-08-18 | 2010-02-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7728029B2 (en) | 2006-03-22 | 2010-06-01 | Hoffmann-La Roche Inc. | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase |
US7741361B2 (en) | 2004-12-27 | 2010-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7790711B2 (en) | 2007-07-17 | 2010-09-07 | Hoffmann-La Roche Inc. | Inhibitors of 11β-Hydroxysteroid Dehydrogenase |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7935703B2 (en) * | 2006-01-17 | 2011-05-03 | Astrazeneca Ab | Piperazines and piperidines as Mglur5 potentiators |
US7947689B2 (en) | 2006-08-04 | 2011-05-24 | Merz Pharma Gmbh & Co. Kgaa | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20120016014A1 (en) * | 2010-07-14 | 2012-01-19 | Indian Institute Of Science | Benzothiophene carboxamide compounds, composition and applications thereof |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8183384B2 (en) | 2006-05-25 | 2012-05-22 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
WO2012017166A3 (fr) * | 2010-07-19 | 2012-07-19 | Vaxconsulting | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
US8236835B2 (en) | 2006-09-22 | 2012-08-07 | Novartis Ag | Heterocyclic inhibitors of stearoyl-CoA desaturase |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8258160B2 (en) | 2006-12-20 | 2012-09-04 | Novartis Ag | SCD1 inhibitors triazole and tetrazole compounds |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8288590B2 (en) | 2006-10-17 | 2012-10-16 | Rutgers, The State University Of New Jersey | N-substituted monomers and polymers |
US8314138B2 (en) | 2006-08-24 | 2012-11-20 | Novartis Ag | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes |
US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
US8513263B2 (en) | 2008-10-22 | 2013-08-20 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US8563591B2 (en) | 2004-08-30 | 2013-10-22 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
CN103420931A (zh) * | 2013-05-02 | 2013-12-04 | 范国煌 | 调节巨噬细胞极化并抗糖尿病的五环化合物及其应用 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8741897B2 (en) | 2003-09-24 | 2014-06-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014139963A1 (en) | 2013-03-13 | 2014-09-18 | Unilever Plc | Cosmetic compositions with tricyclodecane amides |
WO2014139965A1 (en) | 2013-03-13 | 2014-09-18 | Unilever Plc | Photoprotective compositions with tricyclodecane amides |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9012494B2 (en) | 2004-05-07 | 2015-04-21 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9126973B2 (en) | 2008-09-22 | 2015-09-08 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
US9150512B2 (en) | 2004-08-30 | 2015-10-06 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
US9493476B2 (en) | 2010-05-20 | 2016-11-15 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
US9775793B2 (en) | 2013-03-13 | 2017-10-03 | Conopco, Inc. | Prolonged delivery of certain fragrance components from personal care compositions |
US9782414B2 (en) | 2014-11-16 | 2017-10-10 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US9840466B2 (en) | 2013-12-09 | 2017-12-12 | Conopco, Inc. | Process of making adamantanamides |
US9926312B2 (en) | 2013-10-01 | 2018-03-27 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
US10137127B2 (en) | 2016-04-04 | 2018-11-27 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
CN109803951A (zh) * | 2016-11-08 | 2019-05-24 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
US10307426B2 (en) | 2017-05-22 | 2019-06-04 | Genentech, Inc. | Therapeutic compounds and compositions, and methods of use thereof |
US10370727B2 (en) | 2015-10-26 | 2019-08-06 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10500193B2 (en) | 2011-11-02 | 2019-12-10 | Synta Pharmaceuticals Corporation | Combination therapy of HSP90 inhibitors with platinum-containing agents |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
US10696611B2 (en) | 2014-08-29 | 2020-06-30 | Amorepacific Corporation | Adamantane derivative compound |
WO2021045686A1 (en) * | 2019-09-04 | 2021-03-11 | Agency For Science, Technology And Research | Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction |
AU2015342940B2 (en) * | 2014-11-05 | 2021-04-01 | Flexus Biosciences, Inc. | Immunoregulatory agents |
EP3576737A4 (en) * | 2017-02-06 | 2021-04-21 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE |
WO2021092264A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | MrgprX2 ANTAGONISTS AND USES THEREOF |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11426420B2 (en) | 2017-04-07 | 2022-08-30 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
WO2024190948A1 (ko) * | 2023-03-13 | 2024-09-19 | 대구가톨릭대학교산학협력단 | 리도카인 유도체를 유효성분으로 포함하는 항염증용 조성물 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
JP5904944B2 (ja) * | 2009-10-22 | 2016-04-20 | フィブロテック セラピューティクス プロプライエタリー リミテッド | 縮合環類似体の抗線維症剤 |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9381171B2 (en) | 2013-12-19 | 2016-07-05 | Samsung Electronics Co., Ltd. | Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072084A2 (en) * | 2001-03-08 | 2002-09-19 | Sterix Limited | Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity |
WO2002076435A2 (en) * | 2001-03-23 | 2002-10-03 | The University Of Edinburgh | Lipid profile modulation with steroids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089471A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
-
2004
- 2004-04-06 WO PCT/DK2004/000248 patent/WO2004089415A2/en not_active Application Discontinuation
- 2004-04-06 EP EP04725890A patent/EP1615667A2/en not_active Withdrawn
- 2004-04-06 JP JP2006504351A patent/JP2006522744A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072084A2 (en) * | 2001-03-08 | 2002-09-19 | Sterix Limited | Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity |
WO2002076435A2 (en) * | 2001-03-23 | 2002-10-03 | The University Of Edinburgh | Lipid profile modulation with steroids |
Cited By (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US8212040B2 (en) | 2002-03-26 | 2012-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof |
JP2006522748A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
US8741897B2 (en) | 2003-09-24 | 2014-06-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US7563905B2 (en) | 2004-03-12 | 2009-07-21 | Wyeth | Triazole derivatives and method of using the same to treat HIV infections |
WO2005090320A3 (en) * | 2004-03-12 | 2006-04-27 | Wyeth Corp | Triazole derivatives and method of using the same to treat hiv infections |
WO2005090320A2 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | Triazole derivatives and method of using the same to treat hiv infections |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US9302987B2 (en) | 2004-05-07 | 2016-04-05 | Janssen Pharmaceutica N.V. | Pyrrolidinyl derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9012494B2 (en) | 2004-05-07 | 2015-04-21 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9776965B2 (en) | 2004-05-07 | 2017-10-03 | Janssen Pharmaceutica Nv | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
WO2006023844A3 (en) * | 2004-08-20 | 2007-04-19 | Entremed Inc | Compositions and methods comprising proteinase activated receptor antagonists |
WO2006023844A2 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
US9422284B2 (en) | 2004-08-30 | 2016-08-23 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9150512B2 (en) | 2004-08-30 | 2015-10-06 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US9630921B2 (en) | 2004-08-30 | 2017-04-25 | Janssen Pharmaceutica Nv | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
JP2008511580A (ja) * | 2004-08-30 | 2008-04-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 11−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのn−2アダマンタニル−2−フェノキシ−アセトアミド誘導体 |
US8563591B2 (en) | 2004-08-30 | 2013-10-22 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
US8344181B2 (en) | 2004-08-30 | 2013-01-01 | Janssen Pharmaceutica N.V. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
WO2006024627A3 (en) * | 2004-08-30 | 2007-09-13 | Janssen Pharmaceutica Nv | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
EA012263B1 (ru) * | 2004-08-30 | 2009-08-28 | Янссен Фармацевтика Н.В. | Производные n-2-адамантанил-2-феноксиацетамида в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы |
WO2006046915A1 (en) * | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Use of unsaturated quionoline or naphtalene derivatives as medicaments |
US9090569B2 (en) | 2004-11-18 | 2015-07-28 | Synta Pharmaceuticals Corp. | Triazone compounds that modulate HSP90 activity |
JP2008520702A (ja) * | 2004-11-18 | 2008-06-19 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
US8901308B2 (en) | 2004-11-18 | 2014-12-02 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
US7825148B2 (en) | 2004-11-18 | 2010-11-02 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
US8362055B2 (en) | 2004-11-18 | 2013-01-29 | Synta Pharmaceuticals, Inc. | Triazole compounds that modulate HSP90 activity |
US7741361B2 (en) | 2004-12-27 | 2010-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7345058B2 (en) | 2005-04-05 | 2008-03-18 | Hoffmann-La Roche Inc. | Pyrazoles |
WO2006132436A1 (ja) * | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | 複素環化合物 |
JP2008546714A (ja) * | 2005-06-17 | 2008-12-25 | アポジー・バイオテクノロジー・コーポレイション | スフィンゴシンキナーゼ阻害剤 |
US7662813B2 (en) | 2005-08-18 | 2010-02-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
WO2007025892A1 (en) | 2005-08-31 | 2007-03-08 | F. Hoffmann-La Roche Ag | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
US7935703B2 (en) * | 2006-01-17 | 2011-05-03 | Astrazeneca Ab | Piperazines and piperidines as Mglur5 potentiators |
US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7728029B2 (en) | 2006-03-22 | 2010-06-01 | Hoffmann-La Roche Inc. | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase |
WO2007117398A3 (en) * | 2006-03-30 | 2007-12-06 | James E Summerton | Non-peptidic molecules for detecting and treating tumors |
WO2007117398A2 (en) * | 2006-03-30 | 2007-10-18 | Summerton James E | Non-peptidic molecules for detecting and treating tumors |
WO2007139951A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
US8969396B2 (en) | 2006-05-25 | 2015-03-03 | Synta Pharmaceuticals Corp. | Method for treating a B-raf associated cancer with an Hsp90 inhibitor |
US8183384B2 (en) | 2006-05-25 | 2012-05-22 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
WO2007139951A3 (en) * | 2006-05-25 | 2008-12-24 | Synta Pharmaceuticals Corp | Method for treating proliferative disorders associated with protooncogene products |
US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
US7985753B2 (en) | 2006-08-04 | 2011-07-26 | Merz Pharma Gmbh & Co. Kgaa | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators |
WO2008019302A1 (en) * | 2006-08-04 | 2008-02-14 | Decode Genetics Ehf | Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation |
US7947689B2 (en) | 2006-08-04 | 2011-05-24 | Merz Pharma Gmbh & Co. Kgaa | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8314138B2 (en) | 2006-08-24 | 2012-11-20 | Novartis Ag | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes |
US8299054B2 (en) | 2006-08-24 | 2012-10-30 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
WO2008029168A3 (en) * | 2006-09-08 | 2008-05-02 | Summit Corp Plc | Treatment of duchenne muscular dystrophy |
WO2008029168A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
US8236835B2 (en) | 2006-09-22 | 2012-08-07 | Novartis Ag | Heterocyclic inhibitors of stearoyl-CoA desaturase |
RU2470040C2 (ru) * | 2006-10-17 | 2012-12-20 | Ратджерс, Те Стейт Юниверсити Оф Нью Джерси | N-замещенные мономеры и полимеры |
US8288590B2 (en) | 2006-10-17 | 2012-10-16 | Rutgers, The State University Of New Jersey | N-substituted monomers and polymers |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8258160B2 (en) | 2006-12-20 | 2012-09-04 | Novartis Ag | SCD1 inhibitors triazole and tetrazole compounds |
WO2008101886A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008101914A2 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008101885A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008121126A1 (en) * | 2007-03-30 | 2008-10-09 | Summerton James E | Non-peptidic molecules for detecting and treating tumors |
WO2008121386A3 (en) * | 2007-03-30 | 2008-12-31 | Amgen Inc | Calcimimetic compounds for use in the treatment of bowel disorders |
US8093299B2 (en) | 2007-03-30 | 2012-01-10 | Amgen Inc. | Methods of treating bowel disorders |
AU2008233088B2 (en) * | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
WO2008134035A1 (en) * | 2007-04-27 | 2008-11-06 | Panacos Pharmaceuticals, Inc. | Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives |
US7790711B2 (en) | 2007-07-17 | 2010-09-07 | Hoffmann-La Roche Inc. | Inhibitors of 11β-Hydroxysteroid Dehydrogenase |
WO2009015067A2 (en) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2009015067A3 (en) * | 2007-07-25 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8541444B2 (en) | 2007-10-01 | 2013-09-24 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US9504676B2 (en) | 2008-04-09 | 2016-11-29 | Centre National De La Recherche Scientifique | Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules |
WO2009133294A3 (fr) * | 2008-04-09 | 2010-04-08 | Centre National De La Recherche Scientifique | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
FR2929851A1 (fr) * | 2008-04-09 | 2009-10-16 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
WO2009133294A2 (fr) * | 2008-04-09 | 2009-11-05 | Centre National De La Recherche Scientifique | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
US10590139B2 (en) | 2008-09-22 | 2020-03-17 | Array Biopharma Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US9227975B2 (en) | 2008-09-22 | 2016-01-05 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2B]pyridazine compounds |
US9126973B2 (en) | 2008-09-22 | 2015-09-08 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
US10011604B2 (en) | 2008-09-22 | 2018-07-03 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US9796723B2 (en) | 2008-09-22 | 2017-10-24 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US9795611B2 (en) | 2008-09-22 | 2017-10-24 | Array Biopharma, Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US10005783B2 (en) | 2008-10-22 | 2018-06-26 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US8513263B2 (en) | 2008-10-22 | 2013-08-20 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9676783B2 (en) | 2008-10-22 | 2017-06-13 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US10774085B2 (en) | 2008-10-22 | 2020-09-15 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US11267818B2 (en) | 2008-10-22 | 2022-03-08 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US8865698B2 (en) | 2008-10-22 | 2014-10-21 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
US9447104B2 (en) | 2008-10-22 | 2016-09-20 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
US9127013B2 (en) | 2008-10-22 | 2015-09-08 | Array Biopharma, Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US10047097B2 (en) | 2008-10-22 | 2018-08-14 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
US8791123B2 (en) | 2009-07-09 | 2014-07-29 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10251889B2 (en) | 2009-07-09 | 2019-04-09 | Array BioPharm Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
US9682979B2 (en) | 2009-07-09 | 2017-06-20 | Array Biopharma, Inc. | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors |
US9782415B2 (en) | 2009-07-09 | 2017-10-10 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US9796724B2 (en) | 2009-07-09 | 2017-10-24 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10758542B2 (en) | 2009-07-09 | 2020-09-01 | Array Biopharma Inc. | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors |
EP3299372A1 (en) | 2009-07-09 | 2018-03-28 | Array Biopharma, Inc. | Intermediate compounds for the preparation ofsubstituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
US9493476B2 (en) | 2010-05-20 | 2016-11-15 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
US9718822B2 (en) | 2010-05-20 | 2017-08-01 | Array Biopharma, Inc. | Macrocyclic compounds as Trk kinase inhibitors |
US9750744B2 (en) | 2010-05-20 | 2017-09-05 | Array Biopharma, Inc. | Macrocyclic compounds as Trk kinase inhibitors |
US9902741B2 (en) | 2010-05-20 | 2018-02-27 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US10647730B2 (en) | 2010-05-20 | 2020-05-12 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US9840519B2 (en) | 2010-05-20 | 2017-12-12 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US20120016014A1 (en) * | 2010-07-14 | 2012-01-19 | Indian Institute Of Science | Benzothiophene carboxamide compounds, composition and applications thereof |
US8975399B2 (en) | 2010-07-19 | 2015-03-10 | Jean-Francois Zagury | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF |
WO2012017166A3 (fr) * | 2010-07-19 | 2012-07-19 | Vaxconsulting | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
US10500193B2 (en) | 2011-11-02 | 2019-12-10 | Synta Pharmaceuticals Corporation | Combination therapy of HSP90 inhibitors with platinum-containing agents |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9775793B2 (en) | 2013-03-13 | 2017-10-03 | Conopco, Inc. | Prolonged delivery of certain fragrance components from personal care compositions |
WO2014139963A1 (en) | 2013-03-13 | 2014-09-18 | Unilever Plc | Cosmetic compositions with tricyclodecane amides |
US9682028B2 (en) | 2013-03-13 | 2017-06-20 | Conopco, Inc. | Personal care photoprotective compositions with tricyclodecane amides |
US9883997B2 (en) | 2013-03-13 | 2018-02-06 | Conopco, Inc. | Cosmetic compositions with tricyclodecane amides |
WO2014139965A1 (en) | 2013-03-13 | 2014-09-18 | Unilever Plc | Photoprotective compositions with tricyclodecane amides |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CN103420931B (zh) * | 2013-05-02 | 2015-07-08 | 范国煌 | 调节巨噬细胞极化并抗糖尿病的五环化合物及其应用 |
CN103420931A (zh) * | 2013-05-02 | 2013-12-04 | 范国煌 | 调节巨噬细胞极化并抗糖尿病的五环化合物及其应用 |
US9926312B2 (en) | 2013-10-01 | 2018-03-27 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
US10072005B2 (en) | 2013-10-01 | 2018-09-11 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9840466B2 (en) | 2013-12-09 | 2017-12-12 | Conopco, Inc. | Process of making adamantanamides |
US9604984B2 (en) | 2014-05-23 | 2017-03-28 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
US10696611B2 (en) | 2014-08-29 | 2020-06-30 | Amorepacific Corporation | Adamantane derivative compound |
AU2015342940B2 (en) * | 2014-11-05 | 2021-04-01 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11932601B2 (en) | 2014-11-05 | 2024-03-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10172861B2 (en) | 2014-11-16 | 2019-01-08 | Array Biopharma Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10285993B2 (en) | 2014-11-16 | 2019-05-14 | Array Biopharma Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10813936B2 (en) | 2014-11-16 | 2020-10-27 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US9782414B2 (en) | 2014-11-16 | 2017-10-10 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10655186B2 (en) | 2015-10-26 | 2020-05-19 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10370727B2 (en) | 2015-10-26 | 2019-08-06 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10378068B2 (en) | 2015-10-26 | 2019-08-13 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
US10588908B2 (en) | 2016-04-04 | 2020-03-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10668072B2 (en) | 2016-04-04 | 2020-06-02 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10137127B2 (en) | 2016-04-04 | 2018-11-27 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
CN109803951A (zh) * | 2016-11-08 | 2019-05-24 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
CN109803951B (zh) * | 2016-11-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
EP3576737A4 (en) * | 2017-02-06 | 2021-04-21 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE |
US10966985B2 (en) | 2017-03-16 | 2021-04-06 | Array Biopharma Inc. | Macrocyclic compounds as ROS1 kinase inhibitors |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
US11426420B2 (en) | 2017-04-07 | 2022-08-30 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
US10307426B2 (en) | 2017-05-22 | 2019-06-04 | Genentech, Inc. | Therapeutic compounds and compositions, and methods of use thereof |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11702421B2 (en) | 2018-12-31 | 2023-07-18 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
US11845753B2 (en) | 2018-12-31 | 2023-12-19 | Biomea Fusion, Inc. | Inhibitors of menin-mll interaction |
US12077544B2 (en) | 2018-12-31 | 2024-09-03 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
US12116371B2 (en) | 2018-12-31 | 2024-10-15 | Biomea Fusion, Inc. | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
CN114286677A (zh) * | 2019-09-04 | 2022-04-05 | 新加坡科技研究局 | 作为β-连环蛋白/TCF4相互作用调节剂的杂环化合物 |
WO2021045686A1 (en) * | 2019-09-04 | 2021-03-11 | Agency For Science, Technology And Research | Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction |
CN114728919A (zh) * | 2019-11-05 | 2022-07-08 | 德米拉公司 | MrgprX2拮抗剂及其用途 |
WO2021092264A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | MrgprX2 ANTAGONISTS AND USES THEREOF |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
WO2024190948A1 (ko) * | 2023-03-13 | 2024-09-19 | 대구가톨릭대학교산학협력단 | 리도카인 유도체를 유효성분으로 포함하는 항염증용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2004089415A3 (en) | 2005-03-10 |
JP2006522744A (ja) | 2006-10-05 |
EP1615667A2 (en) | 2006-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7501405B2 (en) | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | |
US20060094699A1 (en) | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | |
WO2004089415A2 (en) | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | |
WO2004089416A2 (en) | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent | |
US20090264414A1 (en) | Amide Derivatives and Pharmaceutical Use Thereof | |
US20060111366A1 (en) | Pharmaceutical use of substituted amides | |
US7723323B2 (en) | Pharmaceutical use of fused 1,2,4-triazoles | |
JP2006522750A5 (ja) | ||
JP2006522744A5 (ja) | ||
US8138342B2 (en) | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | |
US8153798B2 (en) | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors | |
EP1615697A2 (en) | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof | |
EP1948190A2 (en) | Pharmaceutical use of substituted amides | |
EP1615637A1 (en) | Pharmaceutical use of substituted 1,2,4-triazoles | |
US20070270408A1 (en) | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | |
JP2006522746A5 (ja) | ||
EP1854487A2 (en) | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | |
EP1862181A2 (en) | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | |
EP1615666A2 (en) | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent | |
EP1785424A2 (en) | Fused 1,2,4-triazoles and pharmaceutical uses thereof | |
EP1782859A2 (en) | Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines | |
MX2008005322A (en) | Pharmaceutical use of substituted amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004725890 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11246814 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006504351 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004725890 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11246814 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004725890 Country of ref document: EP |